Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has brought stumbles for Novo over the past year.

Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy weight-loss drug four years ago, but its shares rose about 6% as the company anticipates a recovery in its biggest market in the U.

First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up